All In Biotech

BLA 020367 · Genzyme

Cerezyme

Imiglucerase · Injection · Hydrolytic Lysosomal Glucocerebroside-specific Enzyme

NovelPriority reviewOrphan

Last checked: Nov 19, 2026Latest source record: Jan 12, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1994

May 23, 1994

Approved uses

2

Original approval plus efficacy supplements

Registered trials

49

20 Phase 3, 0 recruiting

FAERS reports

4,775

3,317 serious, 821 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: HYPERSENSITIVITY REACTIONS INCLUDING ANAPHYLAXIS Patients treated with enzyme replacement therapies have experienced life-threatening hypersensitivity reactions, including anaphylaxis. Anaphylaxis has occurred during the early course of enzyme replacement therapy and after extended duration of therapy. Initiate CEREZYME in a healthcare setting with appropriate medical monitoring and support measures, including access to cardiopulmonary resuscitation equipment. If a severe hypersensitivity reaction (e.g., anaphylaxis) occurs, discontinue CEREZYME and immediately initiate appropriate medical treatment, including use of epinephrine. Inform patients of the symptoms of life-threatening hypersensitivity reactions, including anaphylaxis and to seek immediate medical care should symptoms occur [see Warnings and Precautions (5.1) ] . WARNING: HYPERSENSITIVITY REACTIONS INCLUDING...

What it is approved for

From the label in effect Aug 27, 2026.

CEREZYME is indicated for the treatment of non-central nervous system (CNS) manifestations of Type 1 or Type 3 Gaucher disease in adults and pediatric patients. CEREZYME is a hydrolytic lysosomal glucocerebrosidase-specific enzyme indicated for the treatment of non-central nervous system (CNS) manifestations of Type 1 or Type 3 Gaucher disease in adults and pediatric patients. ( 1 )

Mechanism: Gaucher disease is characterized by a deficiency of β-glucocerebrosidase activity, which results in accumulation of glucocerebroside in various tissues including liver, spleen, and bone marrow. The mannose sugars on imiglucerase mediate binding to and internalization by cells including macrophages. CEREZYME catalyzes the hydrolysis of glucocerebroside to glucose and ceramide.

Therapeutic areas: Rare and genetic disease

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jan 12, 2026 Supplement 123 · Efficacy OrphanLabelLetter
  • May 23, 1994 Original approval · Type 1 - New Molecular Entity · priority review Other
2 products under this application
  • CEREZYME · IMIGLUCERASE 400 UNITS/VIAL · INJECTABLE, INJECTION · Prescription
  • CEREZYME · IMIGLUCERASE 200 UNITS/VIAL · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Imiglucerase" as an intervention, any sponsor and status, largest first.

All 49 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • pyrexia216
  • fatigue192
  • death174
  • fall174
  • pneumonia174
  • weight increased163
  • exposure during pregnancy162
  • dyspnoea151
  • bone pain150
  • weight decreased140
  • malaise137
  • arthralgia130

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004115
2005105
2006123
2007164
2008170
2009233
2010225
2011262
2012172
2013230
2014386
2015273
2016226
2017277
2018213
2019202
2020146
2021201
2022225
2023213
2024196
2025226
2026192

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Cerezyme (Imiglucerase)

2024 spending

$14.3M

Beneficiaries

39

455 claims

Per beneficiary

$365,943

$1,681.80 per unit

View as table
YearSpending
2020$12,987,685
2021$14,987,046
2022$15,732,693
2023$15,164,652
2024$14,271,795

Part B: Cerezyme (Imiglucerase) · HCPCS J1786

2024 spending

$44.2M

Beneficiaries

140

2,260 claims

Per beneficiary

$316,023

2024 ASP limit $43.83 per unit

View as table
YearSpending
2020$35,829,480
2021$39,031,430
2022$43,717,471
2023$45,952,004
2024$44,243,279

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 40 on PubMed

Sponsor: Sanofi

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.